Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients.

Avedissian SN, Rhodes NJ, Ng TMH, Rao AP, Beringer PM.

Pharmacotherapy. 2019 Jun;39(6):718-723. doi: 10.1002/phar.2270. Epub 2019 May 20.

PMID:
31045258
2.

Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.

Park AYJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00550-18. doi: 10.1128/AAC.00550-18. Print 2018 Sep.

3.

Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.

Schaal JB, Tran DQ, Subramanian A, Patel R, Laragione T, Roberts KD, Trinh K, Tongaonkar P, Tran PA, Minond D, Fields GB, Beringer P, Ouellette AJ, Gulko PS, Selsted ME.

PLoS One. 2017 Nov 16;12(11):e0187868. doi: 10.1371/journal.pone.0187868. eCollection 2017.

4.

Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.

Jayne JG, Bensman TJ, Schaal JB, Park AYJ, Kimura E, Tran D, Selsted ME, Beringer PM.

Am J Respir Cell Mol Biol. 2018 Mar;58(3):310-319. doi: 10.1165/rcmb.2016-0428OC.

5.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00988-17. doi: 10.1128/AAC.00988-17. Print 2017 Oct.

6.

Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.

Bensman TJ, Jayne JG, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, Beringer PM.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00154-17. doi: 10.1128/AAC.00154-17. Print 2017 Aug.

7.

Subregional laminar cartilage MR spin-spin relaxation times (T2) in osteoarthritic knees with and without medial femorotibial cartilage loss - data from the Osteoarthritis Initiative (OAI).

Wirth W, Maschek S, Beringer P, Eckstein F.

Osteoarthritis Cartilage. 2017 Aug;25(8):1313-1323. doi: 10.1016/j.joca.2017.03.013. Epub 2017 Mar 27.

8.

Mechanisms of Doxorubicin Toxicity in Pancreatic β-Cells.

Heart EA, Karandrea S, Liang X, Balke ME, Beringer PA, Bobczynski EM, Zayas-Bazán Burgos D, Richardson T, Gray JP.

Toxicol Sci. 2016 Aug;152(2):395-405. doi: 10.1093/toxsci/kfw096. Epub 2016 Jun 2.

9.

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME.

J Antimicrob Chemother. 2016 Jan;71(1):181-8. doi: 10.1093/jac/dkv301. Epub 2015 Oct 3.

10.

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.

Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer PM, Neamati N.

J Chem Inf Model. 2015 Aug 24;55(8):1720-38. doi: 10.1021/acs.jcim.5b00181. Epub 2015 Jul 23.

PMID:
26153616
11.

A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.

Ha H, Bensman T, Ho H, Beringer PM, Neamati N.

Br J Pharmacol. 2014 Mar;171(6):1551-65. doi: 10.1111/bph.12547.

12.

Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells.

Bensman TJ, Nguyen AN, Rao AP, Beringer PM.

Pulm Pharmacol Ther. 2012 Oct;25(5):377-82. doi: 10.1016/j.pupt.2012.06.010. Epub 2012 Jul 4.

PMID:
22771903
13.

Acute care clinical pharmacy practice: unit- versus service-based models.

American College of Clinical Pharmacy, Haas CE, Eckel S, Arif S, Beringer PM, Blake EW, Lardieri AB, Lobo BL, Mercer JM, Moye P, Orlando PL, Wargo K.

Pharmacotherapy. 2012 Feb;32(2):e35-44. doi: 10.1002/PHAR.1042.

PMID:
22392430
14.

Pharmacokinetics of doxycycline in adults with cystic fibrosis.

Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ.

Antimicrob Agents Chemother. 2012 Jan;56(1):70-4. doi: 10.1128/AAC.05710-11. Epub 2011 Oct 24.

15.

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A.

Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. doi: 10.1128/AAC.00173-11. Epub 2011 May 16.

16.

Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

Wong-Beringer A, Joo J, Tse E, Beringer P.

Int J Antimicrob Agents. 2011 Feb;37(2):95-101. doi: 10.1016/j.ijantimicag.2010.10.013. Epub 2010 Dec 3. Review.

PMID:
21130609
17.

Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus.

Beringer PM, Owens H, Nguyen A, Mordwinkin N, Louie S, Mak M, Sattler F.

Pharmacotherapy. 2010 Oct;30(10):1004-10. doi: 10.1592/phco.30.10.1004.

PMID:
20874037
18.

Recommended education for pharmacists as competitive clinical scientists.

Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R; American College of Clinical Pharmacy.

Pharmacotherapy. 2009 Feb;29(2):236-44. doi: 10.1592/phco.29.2.236. No abstract available.

PMID:
19170592
19.

GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis.

Beringer PM, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP.

J Cyst Fibros. 2009 Jan;8(1):19-25. doi: 10.1016/j.jcf.2008.07.004. Epub 2008 Sep 16.

20.

Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.

Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M.

Pharmacotherapy. 2008 Jul;28(7):883-94. doi: 10.1592/phco.28.7.883.

PMID:
18576903
21.

Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.

Liu S, Beringer PM, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B.

J Clin Pharmacol. 2008 Aug;48(8):957-65. doi: 10.1177/0091270008319707. Epub 2008 May 29.

PMID:
18511651
22.

Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis.

Han EE, Beringer PM, Falck P, Louie S, Rao P, Shapiro B, Gill M.

J Antimicrob Chemother. 2006 May;57(5):1017-9. Epub 2006 Mar 13. No abstract available.

PMID:
16533828
23.

Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice.

Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL.

Chest. 2005 Nov;128(5):3711-6.

PMID:
16304338
24.

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.

Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M.

Antimicrob Agents Chemother. 2005 Dec;49(12):5013-7.

25.

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A.

Antimicrob Agents Chemother. 2005 Sep;49(9):3676-81.

26.

Transporters and their impact on drug disposition.

Beringer PM, Slaughter RL.

Ann Pharmacother. 2005 Jun;39(6):1097-108. Epub 2005 May 10. Review. Erratum in: Ann Pharmacother. 2006 Jan;40(1):159.

PMID:
15886292
27.

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.

Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S.

Cancer Chemother Pharmacol. 2005 Jul;56(1):75-82. Epub 2005 Apr 5.

PMID:
15809878
28.

A comparison of phenytoin-loading techniques in the emergency department.

Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M.

Acad Emerg Med. 2004 Mar;11(3):244-52.

29.

Pharmacokinetics of Ibuprofen in children with cystic fibrosis.

Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ.

Clin Pharmacokinet. 2004;43(3):145-56. Review.

PMID:
14871154
30.

Stability and antibacterial activity of cefepime during continuous infusion.

Sprauten PF, Beringer PM, Louie SG, Synold TW, Gill MA.

Antimicrob Agents Chemother. 2003 Jun;47(6):1991-4.

31.

Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease.

Nguyen T, Louie SG, Beringer PM, Gill MA.

Curr Opin Pulm Med. 2002 Nov;8(6):521-8. Review.

PMID:
12394161
32.

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.

Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ.

J Antimicrob Chemother. 2002 Oct;50(4):553-9.

PMID:
12356801
33.
34.

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.

Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.

Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73.

35.

The clinical use of colistin in patients with cystic fibrosis.

Beringer P.

Curr Opin Pulm Med. 2001 Nov;7(6):434-40. Review.

PMID:
11706322
36.

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Aminimanizani A, Beringer P, Jelliffe R.

Clin Pharmacokinet. 2001;40(3):169-87. Review.

PMID:
11327197
37.

Estimation of creatinine clearance in patients with metastatic ovarian cancer.

Montgomery MJ, Beringer PM, Louie SG, Gill MA.

Ther Drug Monit. 2000 Dec;22(6):695-700.

PMID:
11128237
38.

Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.

Beringer PM, Appleman MD.

Curr Opin Pulm Med. 2000 Nov;6(6):545-50. Review.

PMID:
11100967
39.

Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.

Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ.

Antimicrob Agents Chemother. 2000 Apr;44(4):809-13.

40.

New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.

Beringer PM.

Curr Opin Pulm Med. 1999 Nov;5(6):371-7. Review.

PMID:
10570739
41.

Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis.

Beringer PM, Vinks AA, Jelliffe RW.

J Antimicrob Chemother. 1998 Jan;41(1):142-4. Review. No abstract available.

PMID:
9511054
42.

Predictive performance of a vancomycin-aminoglycoside population model.

Beringer PM, Wong-Beringer A, Rho JP.

Ann Pharmacother. 1998 Feb;32(2):176-81.

PMID:
9496400
43.

Economic aspects of antibacterial adverse effects.

Beringer PM, Wong-Beringer A, Rho JP.

Pharmacoeconomics. 1998 Jan;13(1 Pt 1):35-49. Review.

PMID:
10175984
44.

Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin.

Wong-Beringer A, Beringer P, Lovett MA.

Clin Infect Dis. 1997 Oct;25(4):936-7. No abstract available.

PMID:
9356822
45.

Is routine measurement of free phenytoin concentrations rational?

Beringer PM, Rho JP.

Ther Drug Monit. 1995 Aug;17(4):381-2. No abstract available.

PMID:
7482694

Supplemental Content

Loading ...
Support Center